BackCitius Pharmaceuticals- Warrants(02/08/2022) Overview
Citius Pharmaceuticals Inc - Warrants(02/08/2022)

Citius Pharmaceuticals- Warrants(02/08/2022) Return on Equity

Citius Pharmaceuticals- Warrants(02/08/2022) (CTXRW) has a ROE of -86.14%, below the Healthcare sector average of 11.15%.

Get informed when a big investor buys or sells

+ Follow

ROE

-86.14%

Return on Equity

-86.14%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Citius Pharmaceuticals- Warrants(02/08/2022) (CTXRW) FAQ

The latest ROE for CTXRW is -86.14%. That is below the Healthcare sector average of 11.15%. Investors often review this figure alongside Citius Pharmaceuticals- Warrants(02/08/2022)'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, CTXRW currently prints -86.14% for ROE, while the sector average sits near 11.15%. That is roughly 872.3% below the sector mean. Large gaps often invite a closer look at Citius Pharmaceuticals- Warrants(02/08/2022)'s growth, margins, and balance sheet.

Return on Equity shows how effectively Citius Pharmaceuticals- Warrants(02/08/2022) converts resources into returns. At -86.14%, CTXRW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CTXRW's ROE (-86.14%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Citius Pharmaceuticals- Warrants(02/08/2022)'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.